These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7586340)

  • 1. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.
    Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
    Circulation; 1995 Nov; 92(9):2419-25. PubMed ID: 7586340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
    Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
    Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
    Furberg CD; Pitt B; Byington RP; Park JS; McGovern ME
    Am J Cardiol; 1995 Sep; 76(9):60C-63C. PubMed ID: 7572689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
    Lewis SJ; Moye LA; Sacks FM; Johnstone DE; Timmis G; Mitchell J; Limacher M; Kell S; Glasser SP; Grant J; Davis BR; Pfeffer MA; Braunwald E
    Ann Intern Med; 1998 Nov; 129(9):681-9. PubMed ID: 9841599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).
    Byington RP; Furberg CD; Crouse JR; Espeland MA; Bond MG
    Am J Cardiol; 1995 Sep; 76(9):54C-59C. PubMed ID: 7572688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
    Sacks FM; Pfeffer MA; Moye LA; Rouleau JL; Rutherford JD; Cole TG; Brown L; Warnica JW; Arnold JM; Wun CC; Davis BR; Braunwald E
    N Engl J Med; 1996 Oct; 335(14):1001-9. PubMed ID: 8801446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
    Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
    Pitt B; Mancini GB; Ellis SG; Rosman HS; Park JS; McGovern ME
    J Am Coll Cardiol; 1995 Nov; 26(5):1133-9. PubMed ID: 7594023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
    Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
    Plehn JF; Davis BR; Sacks FM; Rouleau JL; Pfeffer MA; Bernstein V; Cuddy TE; Moyé LA; Piller LB; Rutherford J; Simpson LM; Braunwald E
    Circulation; 1999 Jan; 99(2):216-23. PubMed ID: 9892586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
    MacMahon S; Sharpe N; Gamble G; Hart H; Scott J; Simes J; White H
    Circulation; 1998 May; 97(18):1784-90. PubMed ID: 9603532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
    Shepherd J; Gaw A;
    Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
    Keech A; Colquhoun D; Best J; Kirby A; Simes RJ; Hunt D; Hague W; Beller E; Arulchelvam M; Baker J; Tonkin A;
    Diabetes Care; 2003 Oct; 26(10):2713-21. PubMed ID: 14514569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
    Flaker GC; Warnica JW; Sacks FM; Moyé LA; Davis BR; Rouleau JL; Webel RR; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1999 Jul; 34(1):106-12. PubMed ID: 10399998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin trials and goals of cholesterol-lowering therapy after AMI.
    Pedersen TR
    Am Heart J; 1999 Aug; 138(2 Pt 2):S177-82. PubMed ID: 10426879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.